SCHEMBL3208037

SCHEMBL3208037

NS(=O)(=O)NCCc1cccs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CA1 P00915 6/20 0.48
CA2 P00918 6/20 0.48
CA12 O43570 5/20 0.48
CA9 Q16790 5/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PKM P14618 1/20 0.46
CA5A P35218 4/20 0.45
CA7 P43166 2/20 0.45
CA5B Q9Y2D0 2/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CA14 Q9ULX7 2/20 0.44
GPR84 Q9NQS5 1/20 0.43
CA13 Q8N1Q1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7263003 0.82 NPC1 (0.53) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL14380628 0.81 MEN1 (0.55) CA1CA2CA12KDM4EL3MBTL1
SCHEMBL6564813 0.78 TDP1 (0.56) TAAR1SMN1; SMN2CA1CA2KDM4E
SCHEMBL12601569 0.78 SMN1; SMN2 (0.45) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL2840589 0.78 CA1 (0.48) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL10689007 0.77 CYP19A1 (0.48) NPC1RAB9ASMN1; SMN2CA1CA2
SCHEMBL4600838 0.77 NPC1 (0.48) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL3217657 0.76 NPC1 (0.50) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL4067422 0.76 TAAR1 (0.55) TAAR1NPC1RAB9ASMN1; SMN2CA1
SCHEMBL8883079 0.74 ALDH1A1 (0.56) TAAR1NPC1RAB9APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 TAAR1 2831/4885NPC1 1683/4885RAB9A 3599/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 TAAR1 2261/4885NPC1 1377/4885RAB9A 3729/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 TAAR1 2831/4885NPC1 1683/4885RAB9A 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.